CD19 and B-cell chronic lymphocytic leukemia: On the basis of an initial successful experience of using CD19-specific BBζ CAR transduced T cells (termed CTL019) to treat three patients with CLL (NCT01029366) (Porter et al., 2011; Kalos et al., 2011), researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania (CHOP/UPenn) conducted a phase I trial to investigate CTL019 cells for children with R/R B-ALL (NCT01626495) and presented a case report on the first two patients in 2013 (Grupp et al., 2013).